![Sales & Marketing: The Perils of Restructuring Sales Commissions for EKRA](https://www.g2intelligence.com/wp-content/uploads/2023/04/56181_G2_stock_4-1080x675.jpg)
Sales & Marketing: The Perils of Restructuring Sales Commissions for EKRA
...
...
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will apparently continue as stand-alones in the coming year, one because it wants to and the other because it has to.
Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close in mid-2019, is now on indefinite hold due to regulatory antitrust
Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the key deals that did come down over the 4-week period beginning in late September 2019.